Pazopanib for the first-line treatment of patients with advanced and/or metastatic renal cell carcinoma: A NICE single technology appraisal

PharmacoEconomics

Volumn 31, Issue 1, 2013, Pages 15-24

  Kilonzo, Mary ^a   Hislop, Jenni ^a   Elders, Andrew ^a   Fraser, Cynthia ^a   Bissett, Donald ^b   McClinton, Samuel ^b   Mowatt, Graham ^a   Vale, Luke ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b ABERDEEN ROYAL INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; MEDROXYPROGESTERONE; METHAMPHETAMINE; PAZOPANIB; PLACEBO; SUNITINIB; VINBLASTINE;

ALOPECIA; CANCER PALLIATIVE THERAPY; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG SAFETY; DRUG SENSITIVITY; HAZARD RATIO; HUMAN; HYPERTENSION; IMMUNOTHERAPY; INTENTION TO TREAT ANALYSIS; KIDNEY METASTASIS; META ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL (TOPIC); PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SURVIVAL RATE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

CARCINOMA, RENAL CELL; COST-BENEFIT ANALYSIS; DECISION MAKING; DRUG APPROVAL; DRUG COSTS; GREAT BRITAIN; HUMANS; KIDNEY NEOPLASMS; PYRIMIDINES; SULFONAMIDES; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84876273584     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-012-0006-5     Document Type: Review

References (42)

1. National Institute for Health and Clinical Excellence. Guide to the single technology appraisal process. London: NICE; 2009. http://www.nice.org.uk/ media/42D/B3/STAGuideLrFinal.pdf. Accessed 11 Oct 2011.
2. National Institute for Health and Clinical Excellence. Renal cell carcinoma (first line metastatic): pazopanib. London: NICE; 2011. http://guidance.nice.org.uk/TA/WaveCRS1/46. Accessed 12 Oct 2011.
3. Cancer Research UK. Kidney cancer statistics: London: Cancer Research UK; 2010. http://info.cancerresearchuk.org/cancerstats/types/kidney/index.htm. Accessed 10 Oct 2011.
4. Beisland C, Medby PC, Beisland HO. Renal cell carcinoma: gender difference in incidental detection and cancer-specific survival. Scand J Urol Nephrol. 2002;36:414-8.
5. Bretheau D, Lechevallier E, Eghazarian C, Grisoni V, Coulange C. Prognostic significance of incidental renal cell carcinoma. Eur Urol. 1995;27:319-23.
6. National Institute for Health and Clinical Excellence. Renal cell carcinoma-sunitinib: guidance [clinical guideline no. TA169]. London: NICE; 2009. http://guidance.nice.org.uk/TA169/Guidance. Accessed 02 Oct 2011.
7. National Institute for Health and Clinical Excellence. Guide to the methods of technology appraisal. London: NICE; 2008. http://www.nice.org.uk/ media/B52/A7/TAMethodsGuideUpdatedJune2008.pdf. Accessed 01 Oct 2011.
8. Huston TE, Figlin R, Tabesh M. Sunitinib-associated changes in left ventricular ejection fraction (LVEF) in treatment-naive patients with metastatic renal cell carcinoma (mRCC) [abstract no. 370]. ASCO Genitourinary Cancer Symposium, 5-7 Mar 2010, San Francisco.
9. Hawkins RE. Renal cancer quality of life (QOL) in treatment-naive and cytokine pre-treated patients with advanced renal cell carcinoma (RCC) treated with pazopanib: results from a phase III double-blind placebo controlled trial. Eur J Cancer Suppl. 2009;7:428-9.
10. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 2009;27:3584-90.
11. Hancock B, Griffiths G, Ritchie A, Oliver R, Gore M, Mead G. Updated results of the MRC randomised controlled trial of alpha interferon vs MPA in patients with metastatic renal carcinoma. Proc Am Soc Clin Oncol 2000; 19: abstract 1336.
12. Negrier SP. Medroxyprogesterone, interferon alfa-2a, interleukin 2, or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis: results of a randomized controlled trial. Cancer. 2007;110:2468-77.
13. Steineck G, Strander H, Carbin BE, Borgstrom E, Wallin L, Achtnich U, et al. Recombinant leukocyte interferon alpha-2a and medroxyprogesterone in advanced renal cell carcinoma: a randomized trial. Acta Oncol. 1990;29:155-62.
14. Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol. 1999;17:2859-67.
15. Kriegmair M, Oberneder R, Hofstetter A. Interferon alfa and vinblastine versus medroxyprogesterone acetate in the treatment of metastatic renal cell carcinoma. Urology. 1995;45:758-62.
16. Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999;17:2530-40.
17. Kaplan ER, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
18. Cox DR. Regression models and life-tables. J Roy Stat Soc B. 1972;34:187-220.
19. Robins JM, Finkelstein DM. Correcting for noncompliance and dependent censoring in an AIDS clinical trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics. 2000;56:779-88.
20. Robins JM, Tsiatis AA. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Commun Stat Theory Methods. 1991;20:2609-31.
21. GlaxoSmithKline. Pazopanib versus sunitinib in the treatment of locally advanced and/or metastatic renal cell carcinoma (COMPARZ) [ClinicalTrials.gov identifier NCT00720941]. Bethesda: NLM; 2010. http://clinicaltrials.gov/ct2/ show/NCT00720941?term=NCT00720941&rank=1. Accessed 01 Oct 2011.
22. GlaxoSmithKline. Patient preference study of pazopanib versus sunitinib in advanced or metastatic kidney cancer (PISCES) [ClinicalTrials.gov identifier NCT01064310]. Bethesda: NLM; 2010. http://clinicaltrials.gov/ct2/show/ NCT01064310?term=NCT01064310&rank=1. Accessed 01 Oct 2011.
23. Robins JM. Analytic methods for estimating HIV treatment and cofactor effects. In: Ostrow DG, Kessler R, editors. Methodological issues of AIDS mental health research. New York: Plenum Publishing; 1993. p. 213-90.
24. Berry G, Kitchin RM, Mock RA. A comparison of two simple hazard ratio estimators based on the logrank test. Stat Med. 1991;10:749-55.
25. Sculpher M. Single technology appraisal at the UK National Institute for Health and Clinical Excellence: a source of evidence and analysis for decision making internationally. Pharmacoeconomics. 2010;28(5):347-9.
26. Rodgers M, Griffin S, Paulden M, et al. Alitretinoin for severe chronic hand eczema: a NICE single technology appraisal. Pharmacoeconomics. 2010;28(5):351-62.
27. Bagust A, Greenhalgh J, Boland A. Cetuximab for recurrent and/or metastatic squamous cell carcinoma of the head and neck: a NICE single technology appraisal. Pharmacoeconomics. 2010;28(6):439-48.
28. Stevenson M, Pandor A. Febuxostat for the management of hyperuricaemia in patients with gout: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(2):133-40.
29. Scotland G, Waugh N, Royle P, et al. Denosumab for the prevention of osteoporotic fractures in post-menopausal women: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(11):951-61.
30. Dickson R, Bagust A, Boland A, et al. Erlotinib monotherapy for the maintenance treatment of non-small cell lung cancer after previous platinum-containing chemotherapy: a NICE single technology appraisal. Pharmacoeconomics. 2011;29(12):1051-62.
31. McKenna C, Maund E, Sarowar M, et al. Dronedarone for the treatment of atrial fibrillation: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(1):35-46.
32. Holmes M, Carroll C, Papaioannou D. Dabigatran etexilate for the prevention of venous thromboembolism in patients undergoing elective hip and knee surgery: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(2):137-46.
33. Yang H, Craig D, Epstein D, et al. Golimumab for the treatment of psoriatic arthritis: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(4):257-70.
34. Boyers D, Jia X, Jenkinson D, et al. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(6):483-95.
35. Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, et al. Omalizumab for severe persistent asthma in children aged 6-11 years: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(11):991-1004.
36. Whyte S, Pandor A, Stevenson M. Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal. Pharmacoeconomics. 2012;30(12):1119-32.
37. Craig D, Rice S, Paton F, et al. Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation: a NICE single technology appraisal. Pharmacoeconomics. In press.
38. Simpson EL, Fitzgerald P, Evans P, et al. Bivalirudin for the treatment of ST-segment elevation myocardial infarction: a NICE single technology appraisal. Pharmacoeconomics. In press.
39. Armstrong N, Manuela J, van Asselt T, et al. Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal. Pharmacoeconomics. In press.
40. Tosh J, Archer R, Davis S, et al. Golimumab for the treatment of rheumatoid arthritis after the failure of previous disease-modifying anti-rheumatic drugs: a NICE single technology appraisal. Pharmacoeconomics. In press.
41. Kearns B, Lloyd-Jones M, Stevenson M, Littlewood C. Cabazitaxel for the second-line treatment of metastatic hormone refractory prostate cancer: a NICE single technology appraisal. Pharmacoeconomics. In press.
42. Kilonzo M, Hislop J, Elders A, Fraser C, Bissett D, McClinton S, et al. Pazopanib for the first line treatment of patients with advanced and/or metastatic renal cell carcinoma: a single technology appraisal. Southampton: Health Technology Assessment Programme; 2010.